RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Quince Therapeutics ROCE 2024

Quince Therapeutics ROCE

-0.34

Quince Therapeutics Dividend yield

Ticker

QNCX

ISIN

US22053A1079

WKN

A2PHHD

In 2024, Quince Therapeutics's return on capital employed (ROCE) was -0.34, a -33.66% increase from the -0.51 ROCE in the previous year.

Quince Therapeutics Aktienanalyse

What does Quince Therapeutics do?

Cortexyme Inc. is a biotechnology company specializing in the development of therapies for degenerative diseases of the nervous system, particularly Alzheimer's disease. The company was founded in 2012 in South San Francisco by Casey Lynch and Stephen Dominy and has since become a leading company in this field. The origin of Cortexyme stems from the discovery of a new bacteria, Porphyromonas gingivalis (P. gingivalis), made by Lynch, the CEO of Cortexyme. He found that P. gingivalis is present in the vicinity of brain plaques in Alzheimer's patients. This discovery meant that Cortexyme had opportunities to develop prevention and treatment options for degenerative diseases of the nervous system. Cortexyme's business model is based on a combination of R&D (research and development) and precision medicine, enabling them to develop personalized therapy approaches. The company is working to specifically target therapeutic molecules against bacteria associated with Alzheimer's and develop biological solutions that target the bacteria. Cortexyme collaborates with a range of specialists, scientists, and university laboratories to conduct their research. The company also has its own research department focused on the discovery of therapeutics to inhibit or eliminate the growth of P. gingivalis. The company has various divisions focusing on the discovery and development of therapeutics. One division focuses on developing biomarkers to aid the diagnosis of Alzheimer's. Another division is developing targeted antibiotics against P. gingivalis, while a third division focuses on developing therapeutics that inhibit the breakdown of bacteria and plaque in the brain. Cortexyme has also developed several products, including the Alzheimer's drug program Atuzaginstat (COR388), which is currently in Phase III of clinical development. Atuzaginstat aims to inhibit P. gingivalis and has the potential to provide hope to terminally ill Alzheimer's patients. Cortexyme is also working on other products, including COR569 to combat inflammation associated with cognitive decline and COR271 to eliminate bacteria that promote brain inflammation. Overall, Cortexyme has taken a new direction in the exploration of Alzheimer's treatment by investigating the role of bacteria in the disease and developing new therapeutic approaches. The company has positioned itself as a leader in Alzheimer's research and will continue to work on developing innovative therapies and prevention strategies that improve the quality of life for Alzheimer's patients and enhance hope for a cure. Quince Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Quince Therapeutics's Return on Capital Employed (ROCE)

Quince Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Quince Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Quince Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Quince Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Quince Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Quince Therapeutics this year?

The ROCE of Quince Therapeutics is -0.34 undefined this year.

How has the ROCE (Return on Capital Employed) of Quince Therapeutics developed compared to the previous year?

The ROCE of Quince Therapeutics has increased by -33.66% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Quince Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Quince Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Quince Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Quince Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Quince Therapeutics impact the company?

An increase in the ROCE of Quince Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Quince Therapeutics affect the company?

A decrease in ROCE of Quince Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Quince Therapeutics?

Some factors that can affect Quince Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Quince Therapeutics so important for investors?

The ROCE of Quince Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Quince Therapeutics take to improve the ROCE?

To improve the ROCE, Quince Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Quince Therapeutics pay?

Over the past 12 months, Quince Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quince Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Quince Therapeutics?

The current dividend yield of Quince Therapeutics is .

When does Quince Therapeutics pay dividends?

Quince Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quince Therapeutics?

Quince Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Quince Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quince Therapeutics located?

Quince Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quince Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quince Therapeutics from 5/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Quince Therapeutics pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Quince Therapeutics in the year 2023?

In the year 2023, Quince Therapeutics distributed 0 USD as dividends.

In which currency does Quince Therapeutics pay out the dividend?

The dividends of Quince Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Quince Therapeutics

Our stock analysis for Quince Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quince Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.